Feasibility and safety of neoadjuvant laparoscopic hyperthermic intraperitoneal chemotherapy in patients with advanced stage ovarian cancer: a single-center experience

References

• Wright AA, Bohlke K, Armstrong DK, et al. Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2016;34(28):3460–3473. doi:10.1200/JCO.2016.68.6907 z27502591
   PubMed Web of Science ®Google Scholar
• Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 2002;20(5):1248–1259. doi:10.1200/JCO.2002.20.5.124811870167
   PubMed Web of Science ®Google Scholar
• Vergote I, Trope CG, Amant F, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010;363(10):943–953. doi:10.1056/NEJMoa090880620818904
   PubMed Web of Science ®Google Scholar
• Kehoe S, Hook J, Nankivell M, et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet. 2015;386(9990):249–257. doi:10.1016/S0140-6736(14)62223-626002111
   PubMed Web of Science ®Google Scholar
• Sehouli J, Senyuva F, Fotopoulou C, et al. Intra-abdominal tumor dissemination pattern and surgical outcome in 214 patients with primary ovarian cancer. J Surg Oncol. 2009;99(7):424–427. doi:10.1002/jso.2128819365809
   PubMed Web of Science ®Google Scholar
• Berek JS, Kehoe ST, Kumar L, Friedlander M. Cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet. 2018;143(Suppl 2:):59–78. doi:10.1002/ijgo.12614
   PubMed Web of Science ®Google Scholar
• van Driel WJ, Koole SN, Sikorska K, et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med. 2018;378(3):230–240. doi:10.1056/NEJMoa170861829342393
   PubMed Web of Science ®Google Scholar
• Spiliotis J, Halkia E, Lianos E, et al. Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study. Ann Surg Oncol. 2015;22(5):1570–1575. doi:10.1245/s10434-014-4157-925391263
   PubMed Web of Science ®Google Scholar
• Fagotti A, Fanfani F, Ludovisi M, et al. Role of laparoscopy to assess the chance of optimal cytoreductive surgery in advanced ovarian cancer: a pilot study. Gynecol Oncol. 2005;96(3):729–735. doi:10.1016/j.ygyno.2004.11.03115721418
   PubMed Web of Science ®Google Scholar
• Hoskins WJ, McGuire WP, Brady MF, et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol. 1994;170(4):974–9; discussion 9–80. doi:10.1016/s0002-9378(94)70090-7
   PubMed Web of Science ®Google Scholar
• Aletti GD, Dowdy SC, Podratz KC, Cliby WA. Relationship among surgical complexity, short-term morbidity, and overall survival in primary surgery for advanced ovarian cancer. Am J Obstet Gynecol. 2007;197(6):676 e1–7. doi:10.1016/j.ajog.2007.10.49518060979
   PubMed Web of Science ®Google Scholar
• Zivanovic O, Chi DS, Filippova O, Randall LM, Bristow RE, O’Cearbhaill RE. It’s time to warm up to hyperthermic intraperitoneal chemotherapy for patients with ovarian cancer. Gynecol Oncol. 2018;151(3):555–561. doi:10.1016/j.ygyno.2018.09.00730249527
   PubMed Web of Science ®Google Scholar
• Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354(1):34–43. doi:10.1056/NEJMoa05298516394300
   PubMed Web of Science ®Google Scholar
• Tewari D, Java JJ, Salani R, et al. Long-term survival advantage and prognostic factors associated with intraperitoneal chemotherapy treatment in advanced ovarian cancer: a gynecologic oncology group study. J Clin Oncol. 2015;33(13):1460–1466. doi:10.1200/JCO.2014.55.989825800756
   PubMed Web of Science ®Google Scholar
• Crile G Jr. The effects of heat and radiation on cancers implanted on the feet of mice. Cancer Res. 1963;23:372–380.14023863
   PubMed Web of Science ®Google Scholar
• Van der Speeten K, Stuart OA, Sugarbaker PH. Pharmacokinetics and pharmacodynamics of perioperative cancer chemotherapy in peritoneal surface malignancy. Cancer J. 2009;15(3):216–224. doi:10.1097/PPO.0b013e3181a58d9519556908
   PubMed Web of Science ®Google Scholar
• Gesson-Paute A, Ferron G, Thomas F, de Lara EC, Chatelut E, Querleu D. Pharmacokinetics of oxaliplatin during open versus laparoscopically assisted heated intraoperative intraperitoneal chemotherapy (HIPEC): an experimental study. Ann Surg Oncol. 2008;15(1):339–344. doi:10.1245/s10434-007-9571-917943387
   PubMed Web of Science ®Google Scholar
• Yonemura Y, Ishibashi H, Hirano M, et al. Effects of neoadjuvant laparoscopic hyperthermic intraperitoneal chemotherapy and neoadjuvant intraperitoneal/systemic chemotherapy on peritoneal metastases from gastric cancer. Ann Surg Oncol. 2017;24(2):478–485. doi:10.1245/s10434-016-5487-627506661
   PubMed Web of Science ®Google Scholar
• Matsuhashi T, Takeshita T, Yamamoto A, et al. Serum CA 125 level after neoadjuvant chemotherapy is predictive of prognosis and debulking surgery outcomes in advanced epithelial ovarian cancer. J Nippon Med Sch. 2017;84(4):170–176. doi:10.1272/jnms.84.17028978897
   PubMed Web of Science ®Google Scholar
• Pelissier A, Bonneau C, Chereau E, et al. CA125 kinetic parameters predict optimal cytoreduction in patients with advanced epithelial ovarian cancer treated with neoadjuvant chemotherapy. Gynecol Oncol. 2014;135(3):542–546. doi:10.1016/j.ygyno.2014.09.00525223808
   PubMed Web of Science ®Google Scholar
• Mahdi H, Maurer KA, Nutter B, Rose PG. The impact of percent reduction in CA-125 levels on prediction of the extent of interval cytoreduction and outcome in patients with advanced-stage cancer of mullerian origin treated with neoadjuvant chemotherapy. Int J Gynecol Cancer. 2015;25(5):823–829. doi:10.1097/IGC.000000000000043425828750
   PubMed Web of Science ®Google Scholar
• Le T, Faught W, Hopkins L, Fung-Kee-Fung M. Importance of CA125 normalization during neoadjuvant chemotherapy followed by planned delayed surgical debulking in patients with epithelial ovarian cancer. J Obstet Gynaecol Can. 2008;30(8):665–670. doi:10.1016/S1701-2163(16)32914-018786288
   PubMedGoogle Scholar
• Furukawa N, Sasaki Y, Shigemitsu A, et al. CA-125 cut-off value as a predictor for complete interval debulking surgery after neoadjuvant chemotherapy in patients with advanced ovarian cancer. J Gynecol Oncol. 2013;24(2):141–145. doi:10.3802/jgo.2013.24.2.14123653831
   PubMed Web of Science ®Google Scholar
• Tate S, Hirai Y, Takeshima N, Hasumi K. CA125 regression during neoadjuvant chemotherapy as an independent prognostic factor for survival in patients with advanced ovarian serous adenocarcinoma. Gynecol Oncol. 2005;96(1):143–149. doi:10.1016/j.ygyno.2004.09.02015589593
   PubMed Web of Science ®Google Scholar
• Rodriguez N, Rauh-Hain JA, Shoni M, et al. Changes in serum CA-125 can predict optimal cytoreduction to no gross residual disease in patients with advanced stage ovarian cancer treated with neoadjuvant chemotherapy. Gynecol Oncol. 2012;125(2):362–366. doi:10.1016/j.ygyno.2012.02.00622333992
   PubMed Web of Science ®Google Scholar
• Lee YJ, Chung YS, Lee JY, et al. Prognostic significance of CA-125 re-elevation after interval debulking surgery in patients with advanced-stage ovarian cancer undergoing neoadjuvant chemotherapy. Eur J Surg Oncol. 2018;45:644–649.30337203
   PubMed Web of Science ®Google Scholar
• Bristow RE, Chi DS. Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis. Gynecol Oncol. 2006;103(3):1070–1076. doi:10.1016/j.ygyno.2006.06.02516875720
   PubMed Web of Science ®Google Scholar
• Lim MC, Song YJ, Seo SS, Yoo CW, Kang S, Park SY. Residual cancer stem cells after interval cytoreductive surgery following neoadjuvant chemotherapy could result in poor treatment outcomes for ovarian cancer. Onkologie. 2010;33(6):324–330. doi:10.1159/00031382320523098
   PubMedGoogle Scholar
• Onda T, Satoh T, Saito T, et al. Comparison of treatment invasiveness between upfront debulking surgery versus interval debulking surgery following neoadjuvant chemotherapy for stage III/IV ovarian, tubal, and peritoneal cancers in a phase III randomised trial: Japan Clinical Oncology Group Study JCOG0602. Eur J Cancer. 2016;64:22–31. doi:10.1016/j.ejca.2016.05.01727323348
   PubMed Web of Science ®Google Scholar
• Gill SE, McGree ME, Weaver AL, Cliby WA, Langstraat CL. Optimizing the treatment of ovarian cancer: neoadjuvant chemotherapy and interval debulking versus primary debulking surgery for epithelial ovarian cancers likely to have suboptimal resection. Gynecol Oncol. 2017;144(2):266–273. doi:10.1016/j.ygyno.2016.11.02127916269
   PubMed Web of Science ®Google Scholar
• Luo Y, Lee M, Kim HS, Chung HH, Song YS. Effect of neoadjuvant chemotherapy on platinum resistance in stage IIIC and IV epithelial ovarian cancer. Medicine (Baltimore). 2016;95(36):e4797. doi:10.1097/MD.000000000000486427603388
   PubMed Web of Science ®Google Scholar
• Rauh-Hain JA, Nitschmann CC, Worley MJ Jr., et al. Platinum resistance after neoadjuvant chemotherapy compared to primary surgery in patients with advanced epithelial ovarian carcinoma. Gynecol Oncol. 2013;129(1):63–68. doi:10.1016/j.ygyno.2013.01.00923337490
   PubMed Web of Science ®Google Scholar
• Da Costa AA, Valadares CV, Baiocchi G, et al. Neoadjuvant chemotherapy followed by interval debulking surgery and the risk of platinum resistance in epithelial ovarian cancer. Ann Surg Oncol. 2015;22(Suppl 3):S971–S978. doi:10.1245/s10434-015-4623-z26014155
   PubMedGoogle Scholar
• Kessous R, Laskov I, Abitbol J, et al. Clinical outcome of neoadjuvant chemotherapy for advanced ovarian cancer. Gynecol Oncol. 2017;144(3):474–479. doi:10.1016/j.ygyno.2016.12.01728041690
   PubMed Web of Science ®Google Scholar
• Oei AL, Vriend LE, Krawczyk PM, Horsman MR, Franken NA, Crezee J. Targeting therapy-resistant cancer stem cells by hyperthermia. Int J Hyperthermia. 2017;33:1–12.28081679
   PubMed Web of Science ®Google Scholar